BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liguori C, Placidi F, Izzi F, Nuccetelli M, Bernardini S, Sarpa MG, Cum F, Marciani MG, Mercuri NB, Romigi A. Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep Breath 2016;20:277-83. [DOI: 10.1007/s11325-015-1305-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Romigi A, Bari M, Liguori C, Izzi F, Rapino C, Nuccetelli M, Battista N, Bernardini S, Centonze D, Mercuri NB, Placidi F, Maccarrone M. CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS Neurol Disord Drug Targets 2020;19:142-7. [PMID: 32148204 DOI: 10.2174/1871527319666200309115602] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Baiardi S, Pizza F, Polischi B, Moresco M, Abu-Rumeileh S, Plazzi G, Parchi P. Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1. Sleep 2020;43:zsz215. [PMID: 31552425 DOI: 10.1093/sleep/zsz215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 2018;12:2665-75. [PMID: 30214155 DOI: 10.2147/DDDT.S101145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
4 Emam S, Adedoyin A, Geng X, Zaeimbashi M, Adams J, Ekenseair A, Podlaha-murphy E, Sun NX. A Molecularly Imprinted Electrochemical Gas Sensor to Sense Butylated Hydroxytoluene in Air. Journal of Sensors 2018;2018:1-9. [DOI: 10.1155/2018/3437149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Liguori C, Spanetta M, Romoli M, Placidi F, Nardi Cesarini E, Mercuri NB, Costa C. Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mech Ageing Dev 2021;194:111434. [PMID: 33444630 DOI: 10.1016/j.mad.2021.111434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gabelle A, Jaussent I, Bouallègue FB, Lehmann S, Lopez R, Barateau L, Grasselli C, Pesenti C, de Verbizier D, Béziat S, Mariano-Goulart D, Carlander B, Dauvilliers Y; Alzheimer's Disease Neuroimaging Initiative., Multi-Domain Intervention Alzheimer's Prevention Trial study groups. Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Ann Neurol 2019;85:74-83. [PMID: 30387527 DOI: 10.1002/ana.25373] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
7 Romigi A, Centonze D. Oral L-carnitine and pregnancy: real opportunity for narcoleptic women? Sleep Sci 2019;12:124. [PMID: 31879547 DOI: 10.5935/1984-0063.20190060] [Reference Citation Analysis]
8 Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R. Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers (Basel) 2021;13:2612. [PMID: 34073579 DOI: 10.3390/cancers13112612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liguori C, Chiaravalloti A, Nuccetelli M, Izzi F, Sancesario G, Cimini A, Bernardini S, Schillaci O, Mercuri NB, Fabio P. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. J Neurol 2017;264:2215-23. [PMID: 28900724 DOI: 10.1007/s00415-017-8613-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
10 Liguori C, Moresco M, Izzi F, Mercuri NB, Plazzi G, Placidi F. New revolution in the assessment of cerebrospinal fluid orexin‐A: Enzyme‐linked immunosorbent assay! Psychiatry Clin Neurosci 2019;73:194-5. [DOI: 10.1111/pcn.12816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Marques TM, Van Rumund A, Kuiperij HB, Verbeek MM. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. Cerebrospinal Fluid in Neurologic Disorders. Elsevier; 2018. pp. 99-113. [DOI: 10.1016/b978-0-12-804279-3.00007-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Berteotti C, Liguori C, Pace M. Dysregulation of the orexin/hypocretin system is not limited to narcolepsy but has far-reaching implications for neurological disorders. Eur J Neurosci 2021;53:1136-54. [PMID: 33290595 DOI: 10.1111/ejn.15077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol 2021;268:1171-8. [PMID: 32852580 DOI: 10.1007/s00415-020-10131-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
14 Fjell AM, Idland A, Sala-llonch R, Watne LO, Borza T, Brækhus A, Lona T, Zetterberg H, Blennow K, Wyller TB, Walhovd KB. Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. Cerebral Cortex 2018;28:2775-85. [DOI: 10.1093/cercor/bhx157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
15 Liguori C. Orexin and Alzheimer’s Disease. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 305-22. [DOI: 10.1007/7854_2016_50] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]